Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | FASN | P49327 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | FAAH | O00519 | 3/20 | 0.58 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | CNR1 | P21554 | 2/20 | 0.55 |
| ▸ | CNR2 | P34972 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31626922 | 1.00 | ALDH1A1 (0.65) | ALDH1A1MAPTFASNKDM4EFAAH | |
| SCHEMBL2168292 | 1.00 | ALDH1A1 (0.65) | ALDH1A1MAPTFASNKDM4EFAAH | |
| SCHEMBL943272 | 1.00 | ALDH1A1 (0.65) | ALDH1A1MAPTFASNKDM4EFAAH | |
| SCHEMBL905183 | 1.00 | ALDH1A1 (0.65) | ALDH1A1MAPTFASNKDM4EFAAH | |
| SCHEMBL1134778 | 1.00 | ALDH1A1 (0.65) | ALDH1A1MAPTFASNKDM4EFAAH | |
| SCHEMBL5614117 | 1.00 | ALDH1A1 (0.65) | ALDH1A1MAPTFASNKDM4EFAAH | |
| SCHEMBL943539 | 1.00 | ALDH1A1 (0.65) | ALDH1A1MAPTFASNKDM4EFAAH | |
| SCHEMBL943538 | 1.00 | ALDH1A1 (0.65) | ALDH1A1MAPTFASNKDM4EFAAH | |
| SCHEMBL4437384 | 1.00 | ALDH1A1 (0.65) | ALDH1A1MAPTFASNKDM4EFAAH | |
| SCHEMBL943270 | 1.00 | ALDH1A1 (0.65) | ALDH1A1MAPTFASNKDM4EFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070060605-A1 | Compositions and methods for inhibiting platelet activation and thrombosis | FLAUMENHAFT ROBERT C | 2007-03-15 | — | — | US | disclosed |
| US-7166612-B2 | Methods for reducing platelet activation platelet aggregaton or thrombosis | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2007-01-23 | — | — | US | disclosed |
| US-20040147540-A1 | Compositions and methods for inhibiting platelet activation and thrombosis | BETH ISRAEL DEACONESS MEDICAL CENTER | 2004-07-29 | — | — | US | disclosed |
| US-20030050236-A1 | Compounds that enhance tumor death | THE UNIVERSITY OF CHICAGO | 2003-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060605-A1 | Compositions and methods for inhibiting platelet activation and thrombosis | PLA2G7, PLTP, PLAAT2 | ALDH1A1 2786/4885MAPT 4507/4885FASN 566/4885 |
| US-20040147540-A1 | Compositions and methods for inhibiting platelet activation and thrombosis | PLA2G7, PLTP, PLAAT2 | ALDH1A1 2786/4885MAPT 4507/4885FASN 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.